Recently Featured

Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

April 10, 2026
Biogen has announced a strategic pivot towards early-stage assets following its recent $5.6 billion acquisition of Apellis Pharmaceuticals. This move is expected to enhance Biogen’s portfolio in immunology and rare diseases, aligning with the company’s long-term vision to diversify its therapeutic offerings. Chief Financial Officer Robin Kramer highlighted that the merger will not only improve…

Noom Plans Push into Peptides Beyond Weight Loss Drugs

April 9, 2026
The weight loss startup Noom is strategically expanding its focus to include peptides, a class of compounds that are gaining traction for their potential applications in preventive health and longevity. This announcement, made on Wednesday, indicates Noom’s intent to diversify its product offerings beyond its current weight loss solutions. Peptides, while increasingly popular in health…

Immune Response Gene Variants Tied to Earlier Breast Cancer in BRCA1 Carriers

April 9, 2026
Researchers at Tel Aviv University have identified a significant link between damaging variants in innate immunity genes and earlier breast cancer (BC) onset in carriers of the BRCA1 mutation. Through whole exome sequencing of Ashkenazi Jewish women with the BRCA1 risk variant, the study revealed that variants affecting natural killer (NK) cell activation were most…

Requesting an FDA Patient-Led Listening Session

April 9, 2026
The FDA has opened avenues for stakeholders to request Patient-Led Listening Sessions, allowing patients to share their experiences and insights directly with regulators. This initiative underscores the agency’s commitment to incorporating patient perspectives into the drug development and approval processes, a shift that reflects a broader trend towards patient-centered care in the pharmaceutical industry. As…

Ongoing Cases